<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244998</url>
  </required_header>
  <id_info>
    <org_study_id>I 53805</org_study_id>
    <nct_id>NCT00244998</nct_id>
  </id_info>
  <brief_title>Fulvestrant in Treating Patients With Advanced Prostate Cancer</brief_title>
  <official_title>Phase II Study of Fulvestrant (Faslodex®) in Androgen Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using&#xD;
      fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with&#xD;
      advanced prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine if the prostate-specific antigen objective response (complete and partial&#xD;
           response) rate is &gt; 0.2 in patients with androgen-independent advanced prostate cancer&#xD;
           treated with fulvestrant.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive fulvestrant intramuscularly on days 0, 14, and 28. Courses repeat once a&#xD;
      month in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-specific antigen (PSA) objective response rate (complete response [CR] or partial response [PR])</measure>
    <time_frame>Monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Every Month</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>IM</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Advanced disease&#xD;
&#xD;
          -  Must have androgen-independent prostate cancer meeting the following criteria:&#xD;
&#xD;
               -  Evidence of rising prostate-specific antigen (PSA) level and absolute value ≥ 5&#xD;
                  ng/mL based on 2 measurements taken ≥ 2 weeks apart (measurements must be done&#xD;
                  after androgen deprivation [orchiectomy or luteinizing hormone-release hormone&#xD;
                  (LHRH) analogue] and antiandrogen withdrawal)&#xD;
&#xD;
          -  Rising PSA required for ≥ 28 days after antiandrogen or progestational therapy for&#xD;
             prostate cancer (≥ 42 days after bicalutamide or nilutamide)&#xD;
&#xD;
          -  Testosterone &lt; 50 ng/mL (unless surgically castrated)&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  PSA elevation constitutes evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
          -  Neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (transfusion or epoetin alfa allowed)&#xD;
&#xD;
          -  No bleeding diathesis (e.g., disseminated intravascular coagulation or clotting factor&#xD;
             deficiency)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
               -  Gilbert's disease with bilirubin ≤ 3 times upper limit of normal (ULN) allowed in&#xD;
                  the absence of other etiology (e.g., hemolysis-reticulocyte count &lt; 5%) and liver&#xD;
                  function tests normal&#xD;
&#xD;
          -  SGOT and/or SGPT ≤ 2 times ULN&#xD;
&#xD;
          -  INR &lt; 1.6&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No unstable cardiac disease requiring medication&#xD;
&#xD;
          -  No new onset crescendo or rest angina&#xD;
&#xD;
               -  Stable exertional angina allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 3 months&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  No other active malignancy within the past 2 years except nonmelanoma skin cancer or&#xD;
             superficial bladder cancer&#xD;
&#xD;
          -  No history of significant neurologic or psychiatric disorders, including psychotic&#xD;
             disorders, dementia, or seizures&#xD;
&#xD;
          -  No other serious illness or medical condition&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No known hypersensitivity to active or inactive excipients of fulvestrant (e.g.,&#xD;
             castor oil or mannitol)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior retinoids, vaccines, and cytokines are not considered cytotoxic and are allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 1 prior cytotoxic chemotherapy regimen&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior glucocorticoids, antiandrogens, progestational agents, estrogens, and LHRH&#xD;
             analogues are not considered cytotoxic and are allowed&#xD;
&#xD;
          -  At least 4 weeks since prior flutamide (6 weeks for bicalutamide or nilutamide)&#xD;
&#xD;
          -  Concurrent megestrol acetate allowed at a stable dose of ≤ 40 mg/day&#xD;
&#xD;
          -  Concurrent androgen deprivation using LHRH analogues allowed but must continue during&#xD;
             study treatment or orchiectomy is required to maintain castrate levels of testosterone&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Endocrine therapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  Prior cholecalciferol analogues, ketoconazole, aminoglutethimide,&#xD;
             peroxisome-proliferation-activated receptor-gamma agonists or antagonists, or PC-SPES&#xD;
             are not considered cytotoxic and are allowed&#xD;
&#xD;
          -  No prior long-term anticoagulation therapy (antiplatelet therapy allowed)&#xD;
&#xD;
          -  More than 4 weeks since prior investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer therapy (e.g., PC-SPES)&#xD;
&#xD;
          -  No concurrent bisphosphonates unless receiving a stable dose at study entry&#xD;
&#xD;
          -  No concurrent therapy that may alter androgen metabolism or androgen levels&#xD;
&#xD;
          -  No concurrent full anticoagulation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald L. Trump, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2005</study_first_posted>
  <last_update_submitted>March 7, 2013</last_update_submitted>
  <last_update_submitted_qc>March 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

